Suppr超能文献

国家乳腺癌和宫颈癌早期检测项目(NBCCEDP)中医疗服务提供者的宫颈癌筛查与管理实践。

Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).

作者信息

Saraiya Mona, Irwin Kathleen L, Carlin Linda, Chen Xiao, Jain Nidhi, Benard Vicki, Montano Daniel E

机构信息

Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.

出版信息

Cancer. 2007 Sep 1;110(5):1024-32. doi: 10.1002/cncr.22875.

Abstract

BACKGROUND

This study was conducted to describe clinicians serving women in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) with regard to demographic and practice characteristics and their usual practices in cervical cancer screening and abnormal cytology management, as well as human papillomavirus (HPV) test use.

METHODS

The authors analyzed data from a nationally representative survey conducted in 2004 of providers practicing 7 specialties that commonly offer cervical cancer screening. The program providers were compared with nonprogram providers.

RESULTS

Program providers were found to be significantly more likely than nonprogram providers to be midlevel providers and to serve low-income, racial/ethnic minorities who are insured by Medicaid. In addition, they had significantly more patients with abnormal Papanicolaou tests and were more likely to offer onsite colposcopy (57% vs 40%). Program providers were less likely to use liquid-based cytology (LBC) as their sole method for cytology. Approximately 20% of program and nonprogram providers used HPV DNA testing as an adjunct to screening cytology and two-thirds used HPV tests to manage patients with abnormal cytology results. However, many also used HPV testing for reasons not approved by the U.S. Food and Drug Administration (FDA), such as for screening women age <30 years.

CONCLUSIONS

As of mid-2004, program providers served racially and ethnically diverse, low-income patients who are at high risk for cervical cancer compared with nonprogram providers, as intended by this program. Because many providers offered on-site colposcopy, used LBC, and used HPV tests for patients with abnormal cytology results, they are well equipped to reduce the risk of cervical cancer. Many program providers used the HPV test for reasons that were not approved of by the FDA or reimbursed by the NBCCEDP. The results of this survey have informed training materials for program providers, reimbursement policies for LBC and HPV tests, and interventions to discourage inappropriate HPV testing.

摘要

背景

本研究旨在描述参与国家乳腺癌和宫颈癌早期检测项目(NBCCEDP)的临床医生的人口统计学和执业特征,以及他们在宫颈癌筛查和异常细胞学管理方面的常规做法,以及人乳头瘤病毒(HPV)检测的使用情况。

方法

作者分析了2004年对7个通常提供宫颈癌筛查的专业的执业提供者进行的全国代表性调查的数据。将该项目的提供者与非项目提供者进行比较。

结果

发现项目提供者比非项目提供者更有可能是中级提供者,并且为通过医疗补助获得保险的低收入种族/族裔少数群体服务。此外,他们有明显更多巴氏试验异常的患者,并且更有可能提供现场阴道镜检查(57%对40%)。项目提供者不太可能将液基细胞学(LBC)作为其唯一的细胞学方法。大约20%的项目和非项目提供者将HPV DNA检测用作筛查细胞学的辅助手段,三分之二的人使用HPV检测来管理细胞学结果异常的患者。然而,许多人也出于美国食品药品监督管理局(FDA)未批准的原因使用HPV检测,例如对年龄<30岁的女性进行筛查。

结论

截至2004年年中,正如该项目所预期的那样,与非项目提供者相比,项目提供者服务的是种族和族裔多样化、低收入且患宫颈癌风险高的患者。由于许多提供者提供现场阴道镜检查、使用LBC并对细胞学结果异常的患者使用HPV检测,他们有充分的条件降低宫颈癌风险。许多项目提供者使用HPV检测的原因未得到FDA的批准,也未得到NBCCEDP的报销。这项调查的结果为项目提供者的培训材料、LBC和HPV检测的报销政策以及劝阻不适当HPV检测的干预措施提供了信息。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验